Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5316MR)

This product GTTS-WQ5316MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5316MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4058MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ15312MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ11543MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ1562MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ9309MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ1910MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ3721MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ8575MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.